Evidence map›Paper›PMID 34063719›Full record

ReviewMedicina (Kaunas, Lithuania)2021

Percutaneous Left Atrial Appendage Occlusion: An Emerging Option in Patients with Atrial Fibrillation at High Risk of Bleeding.

Giovanni Cimmino, Francesco S Loffredo, Emanuele Gallinoro, Dario Prozzo, Dario Fabiani, Luigi Cante, Gemma Salerno, Maurizio Cappelli Bigazzi, Paolo Golino

Open access · goldAbstract readReview
In one paragraph

Review in Medicina (Kaunas, Lithuania), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Effectiveness and safety of edoxabanFrontiers in pharmacology · 2023
    Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Giovanni CimminoDepartment of Translational Medical Sciences, University of Campania Luigi Vanvitelli, 80131 Naples, Italy.ORCID 0000-0002-3802-7052
Francesco S LoffredoDepartment of Translational Medical Sciences, University of Campania Luigi Vanvitelli, 80131 Naples, Italy.
Emanuele GallinoroDepartment of Translational Medical Sciences, University of Campania Luigi Vanvitelli, 80131 Naples, Italy.
Dario ProzzoDepartment of Translational Medical Sciences, University of Campania Luigi Vanvitelli, 80131 Naples, Italy.
Dario FabianiDepartment of Translational Medical Sciences, University of Campania Luigi Vanvitelli, 80131 Naples, Italy.
Luigi CanteDepartment of Translational Medical Sciences, University of Campania Luigi Vanvitelli, 80131 Naples, Italy.
Gemma SalernoVanvitelli Cardiology Unit, Monaldi Hospital, 80131 Naples, Italy.
Maurizio Cappelli BigazziVanvitelli Cardiology Unit, Monaldi Hospital, 80131 Naples, Italy.
Paolo GolinoDepartment of Translational Medical Sciences, University of Campania Luigi Vanvitelli, 80131 Naples, Italy.
University of Campania "Luigi Vanvitelli" · ITOspedale Monaldi · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atrial fibrillation (AF) is a common cardiac arrhythmia with an estimated prevalence of 1% in the general population. It is associated with an increased risk of ischemic stroke, silent cerebral ischemia, and cognitive impairment. Due to the blood flow stasis and morphology, thrombus formation occurs mainly in the left atrial appendage (LAA), particularly in the setting of nonvalvular AF (NVAF). Previous studies have shown that >90% of emboli related to NVAF originate from the LAA, thus prevention of systemic cardioembolism is indicated. According to the current guidelines, anticoagulant therapy with direct oral anticoagulants (DOACs) or vitamin K antagonists (VKAs), represents the standard of care in AF patients, in order to prevent ischemic stroke and peripheral embolization. Although these drugs are widely used and DOACs have shown, compared to VKAs, non-inferiority for stroke prevention with significantly fewer bleeding complications, some issues remain a matter of debate, including contraindications, side effects, and adherence. An increasing number of patients, indeed, because of high bleeding risk or after experiencing life-threatening bleedings, must take anticoagulants with extreme caution if not contraindicated. While surgical closure or exclusion of LAA has been historically used in patients with AF with contradictory results, in the recent years, a novel procedure has emerged to prevent the cardioembolic stroke in these patients: The percutaneous left atrial appendage occlusion (LAAO). Different devices have been developed in recent years, though not all of them are approved in Europe and some are still under clinical investigation. Currently available devices have shown a significant decrease in bleeding risk while maintaining efficacy in preventing thromboembolism. The procedure can be performed percutaneously through the femoral vein access, under general anesthesia. A transseptal puncture is required to access left atrium and is guided by transesophageal echocardiography (TEE). Evidence from the current literature indicates that percutaneous LAAO represents a safe alternative for those patients with contraindications for long-term oral anticoagulation. This review summarizes scientific evidences regarding LAAO for stroke prevention including clinical indications and an adequate patient selection.

Indexed as

Atrial AppendageAtrial FibrillationStrokeAnticoagulantsEuropeHemorrhageHumansTreatment OutcomeAnticoagulantsatrial fibrillationbleeding riskcardioembolismleft atrial appendage occlusionstroke prevention

Identifiers

PMID34063719
PMCPMC8147783
OpenAlexW3157608731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.